Panel discussion

ESH eLearning, Faculty / Presenters, 314093

Maintenance therapy

ESH eLearning, Graham Jackson, 314092

US point of view on new trials (including explanation of why HSCT is not proposed frontline)

ESH eLearning, PAUL RICHARDSON, 314091

Panel discussion

ESH eLearning, Faculty / Presenters, 314090

Fit vs frail: The point of view of North America

ESH eLearning, Hira Mian, 314089

Fit vs Frail: the European point of view

ESH eLearning, Sonja Zweegman, 314088

Panel discussion

ESH eLearning, Faculty / Presenters, 314086

Frailty assessment at diagnosis

ESH eLearning, Alessandra Larocca, 314085

Genetics and risk assessment

ESH eLearning, Hervé Avet-Loiseau, 314084

Diagnostic criteria and initial workup

ESH eLearning, Shaji Kumar, 314083

Panel discussion

ESH eLearning, Faculty / Presenters, 314082

Clinical trials

ESH eLearning, María-Victoria Mateos, 314081

High-risk smoldering : what is the exact definition 

ESH eLearning, Irene Ghobrial, 314080

Selected Abstract: High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study

ESH eLearning, Massimo BRECCIA, 336776

Selected Abstract: Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia

ESH eLearning, James Januzzi, 336775

" CML management in war and peace: lessons that shaped future approaches

ESH eLearning, Sabira Kurtovic, 336773

Voting and Discussion

ESH eLearning, Faculty / Presenters, 336771

For

ESH eLearning, Giuseppe Saglio, 336770

Discussion

ESH eLearning, Faculty / Presenters, 336768

Computational Pathology: Towards Precision Medicine

ESH eLearning, Andrew Janowczyk, 336767

Discussion

ESH eLearning, Giovanni Martinelli, 336766

Human evolutionary genomic medicine

ESH eLearning, Melissa Ilardo, 336765

Discussion

ESH eLearning, Faculty / Presenters, 336764

Selected Abstract: Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia

ESH eLearning, Robert Peter GALE, 336763

Selected Abstract: Chronic Myeloid Leukemia Patients’ Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions

ESH eLearning, Giora Sharf, 336762

Discussion

ESH eLearning, Delphine Agnes, 336761

Keynote presentation Successful TFR in CML: is it predictable?

ESH eLearning, Yong Agnes, 336760

Discussion

ESH eLearning, Faculty / Presenters, 336759

Selected Abstract: Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients

ESH eLearning, Katia Pagnano, 336758

Selected Abstract: High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry

ESH eLearning, Johan Richter, 336757

High dimensional single-cell analysis to predict TFR at the time of CML diagnosis

ESH eLearning, Vaidehi Krishnan, 336755

Discussion

ESH eLearning, Faculty / Presenters, 336753

Selected Abstract: Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study

ESH eLearning, Sung-Hyun Kim, 336752

Selected Abstract: Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib

ESH eLearning, Jorge Cortes, 336751

Discussion

ESH eLearning, Giantonio Rosti, 336750

Keynote presentation Citius, Altius, Fortius ?

ESH eLearning, Andreas Hochhaus, 336749

Discussion

ESH eLearning, Faculty / Presenters, 336748

Investigating secretome and sheddome composition with proteomic approaches

ESH eLearning, Oliver Schilling, 336747

MS-proteomics to uncover the complexity and function of the cell secretome

ESH eLearning, Sara Zanivan, 336746

Discussion

ESH eLearning, Faculty / Presenters, 336745

Bispecific antibodies in leukemia

ESH eLearning, Roland B. Walter, 336744

Checkpoint inhibitors

ESH eLearning, Justin Kline, 336743

Leukemia vaccines

ESH eLearning, David Scheinberg, 336741

Discussion

ESH eLearning, Faculty / Presenters, 336740

Selected Abstract: Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias

ESH eLearning, Eleonora Mäkelä, 336739

Selected Abstract: UNX1 Mutations in Blast Phase Chronic Myeloid Leukemi

ESH eLearning, Shady Adnan Awad, 336738

Keynote presentation CRISPR predictions about relaps in CML

ESH eLearning, Daniel Bolon, 336736

Discussion

ESH eLearning, Rob Welner, 336735

Special Lecture The seed and the soil - the leukemia stem cell in its niche and the quest for cure

ESH eLearning, Ravi Bhatia, 336734

Discussion

ESH eLearning, Daniela Krause, 336732

Keynote presentation Regulation of hematopoietic stem and progenitor cells by the bonemarrow microenvironment

ESH eLearning, Ralf Adams, 336731

Discussion

ESH eLearning, Faculty / Presenters, 336730

Selected Abstract: Molecular Status 36 Months after TKI-Discontinuatíon in CML Is Highly Predictive for Later Loss of MMR - a Report from after−SKI.

ESH eLearning, Johan Richter, 336729

Selected Abstract: Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib

ESH eLearning, Jorge Cortes, 336728

Selected Abstract: Tgfβr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment

ESH eLearning, Bac Viet Le, 336727

Selected Abstract: Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure

ESH eLearning, Susan Branford, 336726

Case-based lecture: Use of blinatumomab in ALL

ESH eLearning, Anita RIJNEVELD, 312788

Case-based lecture: CAR T-cells for precursor B-cell ALL

ESH eLearning, Françoise Méchinaud, 312789

Case-based lecture: Immune check-point inhibitors in acute leukaemia

ESH eLearning, Naval Daver, 312790

Panel discussion

ESH eLearning, Faculty / Presenters, 312791

Standard and new options for T-ALL

ESH eLearning, David Teachey, 312792

Discussion

ESH eLearning, Faculty / Presenters, 312793

Detectable minimal measurable disease by flow cytometry before allogeneic transplantation is a factor of poor outcomes in acute myeloid leukemia

ESH eLearning, Claudia Nunez-Torron Stock, 312786

Case-based lecture: Addition of gemtuzumab ozogamicin to front line 3+7 chemotherapy

ESH eLearning, Juliette Lambert, 312772

Case-based lecture: Nucleoside analogues in high-risk AML

ESH eLearning, Nigel Russell, 312773

Updated results from a phase 1 study of Gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML

ESH eLearning, Alexander Perl, 312774

Panel discussion

ESH eLearning, Faculty / Presenters, 312775

Current intensive therapy of older AML patients in 2020

ESH eLearning, Thomas Braun, 312776

Liposomal daunorubicin/cytarabine

ESH eLearning, Jorge Cortes, 312777

Defining the role of Venetoclax in older patients with AML

ESH eLearning, Andrew Wei, 312778

Discussion

ESH eLearning, Faculty / Presenters, 312779

Targeted agents

ESH eLearning, Ali Bazarbachi, 312781

Discussion

ESH eLearning, Faculty / Presenters, 312782

Case-based lecture: Prevention and treatment of VOD - 100 years after the “Senecio Disease”

ESH eLearning, Sergio Giralt, 312785

Case-based lecture: New GvHD prophylactic/curative treatment

ESH eLearning, Jean-Hugues Dalle, 312783

Case-based lecture: Haplo-identical HSCT with acute leukaemia

ESH eLearning, Jorge Sierra, 312784

Panel discussion

ESH eLearning, Faculty / Presenters, 312787

Case-based lecture: Midostaurin

ESH eLearning, Jorge Sierra, 312771

Yes

ESH eLearning, Charles Craddock, 312762

Case-based lecture: Mixed phenotype acute leukaemias (B/M)

ESH eLearning, Charles Mullighan, 312749

Case-based lecture: Interface acute leukaemias (T/M)

ESH eLearning, Jonathan Bond, 312750

Case-based lecture: Germline predisposition to AML

ESH eLearning, Lucy Godley, 312751

Dasatinib inhibits FLT3/itd and PTPN11 mutated acute myeloid leukemia cells overexpressing SRC Tyrosine kinases

ESH eLearning, Nathali Kaushanski, 312752

Panel discussion

ESH eLearning, Faculty / Presenters, 312753

Case-based lecture: Flow identification and monitoring of leukaemia stem cells

ESH eLearning, Jacqueline Cloos, 312754

Panel discussion

ESH eLearning, Faculty / Presenters, 312761

Case-based lecture: MRD monitoring in Ph-positive ALL

ESH eLearning, Emmanuelle Clappier, 312755

Circulating microRNAs behaving as minimal residual disease biomarkers in childhood ALL

ESH eLearning, Daniel Janos Erdélyi, 312756

Panel discussion

ESH eLearning, Faculty / Presenters, 312757

Case-based lecture: Ph-like ALL diagnosis

ESH eLearning, Sabina Chiaretti, 312758

Case-based lecture: Minimal / optimal gene panel in ALL ?

ESH eLearning, Josep-Maria Ribera, 312759

Case-based lecture: Minimal / optimal gene panel in AML ?

ESH eLearning, Lars Bullinger, 312760

Discussion

ESH eLearning, Faculty / Presenters, 312769

The role of IDH1/2 inhibitors as monotherapy

ESH eLearning, Courtney DiNardo, 312768

Next-generation FLT3 inhibitors

ESH eLearning, Alexander Perl, 312767

Mutation-based therapy off-label - GO for AML salvage therapy

ESH eLearning, Nicolas Boissel, 312766

Targeted therapy for Ph-like ALL

ESH eLearning, Sarah Tasian, 312765

Discussion

ESH eLearning, Faculty / Presenters, 312764

No

ESH eLearning, Gail Roboz, 312763

Keynote lecture: COVID 19 and AML

ESH eLearning, Jorge Sierra, 312748